It's owned by the Piramal Group which is a $3B company.
http://neuraceq.com/
Interesting...
"Neuraceq is an adjunct to other diagnostic evaluations.
Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder.
Safety and effectiveness of Neuraceq have not been established for:
Predicting development of dementia or other neurologic conditions;
Monitoring responses to therapies."
This part of the chairman's blog you linked to was helpful and would explain Amarantus's approach with IUO.
"In total, 900 total patient samples were required for FDA approval of Neuraceq between disease and control arms, and we believe this may serve as a roadmap for ultimate regulatory approval for LymPro."
http://neuraceq.com/
Interesting...
"Neuraceq is an adjunct to other diagnostic evaluations.
Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder.
Safety and effectiveness of Neuraceq have not been established for:
Predicting development of dementia or other neurologic conditions;
Monitoring responses to therapies."
This part of the chairman's blog you linked to was helpful and would explain Amarantus's approach with IUO.
"In total, 900 total patient samples were required for FDA approval of Neuraceq between disease and control arms, and we believe this may serve as a roadmap for ultimate regulatory approval for LymPro."
